Status:
COMPLETED
Comparing the Effects of Sublingual Estradiol Treatment Versus Oral Estradiol With Cyproterone Acetate (CPA) Treatment on The Coagulation System in Transgender Women: A Prospective, Controlled Cohort Study
Lead Sponsor:
Tel-Aviv Sourasky Medical Center
Conditions:
Gender Dysphoria, Adult
Blood Coagulation
Eligibility:
MALE
18-45 years
Phase:
NA
Brief Summary
The goal of this clinical trial is to learn about the effects of different routes of estradiol administration on blood clotting in transgender women starting gender-affirming hormone therapy. The main...
Eligibility Criteria
Inclusion
- Self-identified transgender women
- Aged 18 to 45 years
- Healthy individuals
- Treatment-naïve (not previously exposed to gender-affirming hormone therapy)
- Presenting for gender-affirming hormone therapy (GAHT)
- Provided written informed consent
Exclusion
- Active smokers
- Personal or family history of venous thromboembolism (VTE) or thrombophilia
- History of malignancy in the past 5 years
- Chronic liver disease
- Chronic kidney disease
- Hyperlipidemia
Key Trial Info
Start Date :
November 10 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 10 2024
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT07145281
Start Date
November 10 2022
End Date
November 10 2024
Last Update
August 28 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tel Aviv Sourasky Medical Center - Institute of Endocrinology, Metabolism and Hypertension
Tel Aviv, Israel